Learn more about whether Glaukos Corporation or Inari Medical, Inc. is a better investment based on AAII's A+ Investor grades ...

NARI continues to gain from its expanded product portfolio. The company's expansion in China and Japan bodes well.

Rose brings medical device leadership and commercialization expertise to the company as it prepares to enter into U.S. and European pivotal clinical trials of UroActive, the first smart automated ...

Learn more about whether Inari Medical, Inc. or DENTSPLY SIRONA Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

Perched on a wooded hillside in southern Kyoto, Fushimi Inari is a 1,300-year-old temple dedicated to Inari, the Shinto deity of rice and sake (Japanese rice wine). The shrine complex dates back ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Inari Medical Inc., one of Orange County’s fastest-growing medical device makers, is being acquired for $4.9 billion by global medical technology company Stryker Corp. Stryker on Jan. 6 announced an ...

In this article, we are going to take a look at where Inari Medical Inc. (NASDAQ:NARI) stands against the other stocks. Ten companies finished stronger this week, outpacing the broader market ...

Irvine-based Inari Medical Inc. will be acquired by Stryker Corp. for $4.8 billion. The boards of directors of both companies have approved the transaction, and it’s expected to close in the ...

Acquisition expected to strengthen Stryker’s neurovascular business with Inari VTE product portfolio including mechanical thrombectomy solutions for peripheral vascular diseases such as deep vein ...

Device design with users in mind can increase adoption of smoke evacuation systems in operating rooms as new rules roll out. Modern coronary and peripheral interventional medicine and the ever-growing ...

Stryker's acquisition of Inari for $4.9B enhances its neurovascular portfolio and boosts revenue growth by 50bp, with minimal dilution. Inari shareholders are getting a fair price relative to the ...